




UK Health
Security
Agency

UK Standards for Microbiology Investigations

Investigation of samples from paranasal sinuses



National Institute for Health and Care Excellence (NICE) has renewed accreditation of the process used by the **UK Health Security Agency** to produce **UK Standards for Microbiology Investigations (UK SMIs)**. The renewed accreditation is valid until **30 June 2026** and applies to guidance produced using the processes described in '**UK Standards for Microbiology Investigations Development Process**' (2021). The original accreditation term began on 1 July 2011.

Acknowledgments

UK Standards for Microbiology Investigations (UK SMIs) are developed under the auspices of UKHSA working in partnership with the partner organisations whose logos are displayed below and listed on [the UK SMI website](#). UK SMIs are developed, reviewed and revised by various working groups which are overseen by a [steering committee](#).

The contributions of many individuals in clinical, specialist and reference laboratories who have provided information and comments during the development of this document are acknowledged. We are grateful to the medical editors for editing the medical content.

UK SMIs are produced in association with:



Displayed logos correct as of June 2024.

Contents

Acknowledgments	2
Contents	3
Amendment table	4
1 General information	6
2 Scientific information	6
3 Scope of document	6
4 Introduction	7
5 Safety considerations	10
6 Pre-laboratory processes (pre analytical stage)	11
7 Laboratory processes (analytical stage)	12
8 Post-laboratory processes (post analytical stage)	19
9 Antimicrobial susceptibility testing	22
10 Referral to reference or specialist testing laboratories	22
Algorithm: Investigation of samples from paranasal sinuses	23
References	24

Amendment table

Each UK SMI document has an individual record of amendments. The amendments are listed on this page. The amendment history is available from standards@ukhsa.gov.uk.

Any alterations to this document should be controlled in accordance with the local document control process.

Amendment number/date	12/16.09.24
Issue number discarded	7.1
Insert issue number	8
Anticipated next review date*	16.09.27
Section(s) involved	Amendment
Title	The title has been changed from 'Investigation of nasal samples' to 'Investigation of samples from paranasal sinuses'.
Whole document	<p>Hyperlinks updated to direct reader from UK SMIs webpages on GOV.UK to RCPATH website.</p> <p>The term 'Sinusitis' has been replaced with 'Rhinosinusitis' throughout the document.</p> <p>Subheadings have been revised and modified where needed.</p> <p>All sections have been updated with current and relevant information and supported with recent literature where available.</p> <p>Some sections have been restructured as appropriate to align with current laboratory practices.</p>
Scope of document	<p>Types of specimens have been moved to Section 6: Pre-laboratory processes (pre analytical stage).</p> <p>Other diagnostic methods are considered within the scope but not detailed in the document, emphasising that the diagnosis of rhinosinusitis involves multiple approaches.</p> <p>Topics that are outside the scope of this document have been mentioned and links to relevant UK SMIs were provided if available.</p> <p>The reader is also made aware of the updated taxonomy of <i>Candida</i> species.</p>

Section 4: Introduction	Information updated and supported with recent literature where available. Section on nasal carriage has been removed and the link to UK SMI B 29: Investigation of specimens for screening for MRSA has been provided in the scope.
Technical Information/Limitations	This section has been removed. Information replaced with a link to refer reader to scientific information . Information regarding limitations of diagnostic methods has been incorporated into the relevant sections specific to each method.
Table 1. Culture media, conditions, and organisms	Table has been reviewed and updated.
Table 2. Minimum level of identification in the laboratory	Table has been reviewed and updated.
Section: 7 Laboratory processes (analytical stage)	Sections 7.5 molecular assays and 7.6 Antigen/antibody testing have been added.
Section 9: Antimicrobial susceptibility testing	Information and hyperlinks reviewed and updated as appropriate. Hyperlink to British Society for Antimicrobial Chemotherapy (BSAC) removed. Hyperlink to Clinical and Laboratory Standards Institute (CLSI) added.
Section 10: Referral to reference or specialist testing laboratories	Hyperlinks were updated as appropriate.
Algorithm	The content of the algorithm has been reviewed and updated to align with the document.
References	References reviewed and updated.

*Reviews can be extended up to 5 years where appropriate.

1 General information

[View general information](#) related to UK SMIs.

2 Scientific information

[View scientific information](#) related to UK SMIs.

3 Scope of document

This UK Standards for Microbiology Investigations (UK SMIs) document describes the examination of sinus aspirates and associated samples for the detection and recovery of the organisms that cause the various forms of rhinosinusitis. This document does not cover investigations for conditions of viral, allergic or toxin origin.

Other diagnostic techniques such as Computed Tomography (CT) scans are commonly employed by healthcare professional for the diagnosis of rhinosinusitis and should be considered alongside the microbial methods mentioned in this document.

Please refer to [UK SMI B 29 - Investigation of Specimens for Screening for MRSA](#) for information on screening for MRSA nasal carriage.

Please note the following:

This document does not provide the details for the identification of organisms causing rhinosinusitis. The identification section in this document only provides information on the level to which organisms should be identified to as part of the reporting process with direct links to the relevant identification documents for reference.

This document addresses samples sent to clinical laboratories from both primary and secondary (hospital) healthcare. However, most cases of rhinosinusitis are diagnosed and managed in primary healthcare settings without the necessity of sending samples to clinical laboratories. Also, most cases are uncomplicated and tend to resolve on their own without further investigations or antimicrobial treatment. For more information, refer to the NICE guideline on [Sinusitis \(acute\): antimicrobial prescribing](#) and to their website for information on the management of [acute](#) and [chronic](#) rhinosinusitis and [prescribing information](#).

The advancement of molecular phylogenetic analysis has greatly influenced the taxonomy of microorganisms, especially fungi. This has resulted in the reclassification and renaming of many species. For the purpose of this document, both the previous and current nomenclature of reclassified species or species with updated nomenclature will be mentioned, as required. This also applies to the species formerly part of the genus *Candida* and will collectively be referred to as '*Candida* and associated ascomycetous yeast' (1).

This UK SMI should be used in conjunction with other relevant UK SMIs.

4 Introduction

4.1 Rhinosinusitis

Rhinosinusitis refers to inflammation in the nasal mucosa and one or more of the paranasal sinuses: maxillary, ethmoid, frontal and sphenoid, with the maxillary being the commonest sinus to get infected (2). It can result from viral, bacterial, or fungal infections (2,3). Clinical presentations of rhinosinusitis are diverse and can overlap with other conditions such as hay fever. Symptoms include nasal congestion and discharge, facial pain, pressure or fullness, headaches and fatigue. Factors that predispose an individual to rhinosinusitis include impaired mucociliary function, obstruction of the sinus entrance (e.g., by nasotracheal intubation or by mucosal oedema as a result of viral infection) and defects in the immune system (4-6). The sinus cavities are usually sterile or may contain small numbers of bacteria that are continuously removed by the mucociliary system.

Rhinosinusitis aspiration is generally the preferred method for specimen collection as it allows more targeted sampling and reduces risk of contamination by upper respiratory tract flora (2,7). Specimens should be collected by Ear, Nose and Throat (ENT) surgeons and obtained through rigid endoscopy and careful aspiration of the sinus cavity avoiding contamination by upper respiratory tract flora.

In the case of suspected invasive fungal rhinosinusitis, a biopsy sample may also be obtained for direct microscopic examination prior to culture to identify the presence of fungal elements (8,9).

4.1.1 Acute rhinosinusitis

Acute rhinosinusitis is often suspected if the symptoms meet clinical criteria and deteriorate after 5 days or persist beyond 10 days (less than 12 weeks) (6). The aetiology of community acquired infections can be viral, bacterial, mixed (viral and bacterial) or occasionally fungal (particularly in immunosuppressed patients) with viral upper respiratory tract infections being the most common cause of acute rhinosinusitis.

For acute rhinosinusitis, routine culture and antibiotic prescription is not recommended as acute rhinosinusitis often resolves on its own without the need for antibiotics (7,10).

Culture is selectively obtained in individuals at high risk of complications or antibiotic resistance. Antibiotic prescription is often reserved for patients with persistent or worsening symptoms or complications of acute rhinosinusitis (10). Serious complications of acute rhinosinusitis resulting in the formation of abscess such as subperiosteal abscess or brain abscess may also require surgical intervention and drainage.

Community rhinosinusitis

The most common bacteria isolated from cases of acute community acquired rhinosinusitis are *Streptococcus pneumoniae*, non-typeable *Haemophilus influenzae* (NTHi) and *Moraxella catarrhalis* which is more prevalent in children than adults (2,11,12). Other less common organisms isolated are streptococci of the “anginosus” group (*Streptococcus anginosus*, *Streptococcus constellatus* and *Streptococcus*

intermedius), group A streptococcus, other α -haemolytic streptococci, *Staphylococcus aureus* and anaerobic bacteria (which are infrequent in children) (2,13).

Nosocomial rhinosinusitis

Nosocomial rhinosinusitis is often a complication in endotracheal intubation and mechanical ventilation and often shows no clinical signs of infection (14,15). The causative organisms can vary and infections are often polymicrobial. *Pseudomonas aeruginosa* and other Gram-negative rods commonly cause nosocomial rhinosinusitis in intensive care and immunocompromised patients (2,16). Similar pathogens and polymicrobial infections have been identified in children with more anaerobes being isolated (17,18). Acute fungal rhinosinusitis caused by *Aspergillus* or Mucorales species can occur in immunosuppressed patients, such as haematology patients undergoing chemotherapy, allogeneic or solid-organ transplantation recipients and patients with poorly controlled diabetes.

Nosocomial infections are often underestimated and difficult to diagnose in intensive care patients, therefore close collaboration among physicians, ENT surgeons, microbiologists and histopathologists is necessary to reach a diagnosis.

4.1.2 Chronic rhinosinusitis

Chronic rhinosinusitis is a long-term inflammation of the sinuses that last for longer than 12 weeks without complete resolution (6). Chronic rhinosinusitis is multifactorial in nature and can include allergies, anatomical abnormalities, environmental irritants, and infections including odontogenic infections and those associated with biomaterials such as dental implants. It may also be a feature of some congenital immunodeficiency syndromes and disorders of mucociliary function, although most patients do not have these conditions. In addition, chronic rhinosinusitis can persist in some patients even after surgical intervention.

Chronic rhinosinusitis is clinically sub-categorised by the presence or absence of nasal polyps (CRSwNP or CRSsNP respectively) (5,6). Further research and understanding of chronic rhinosinusitis have led to the proposal of additional categorisation models to enhance the accuracy of diagnosis and management of different subgroups of patients (5,6,19,20).

Mucosal inflammation in chronic rhinosinusitis can persist based on the immune responses. Type 2 immune response can lead to persistent mucosal inflammation and is a characteristic of CRSwNP, especially in western countries. Type 1 inflammation is more commonly associated with CRSsNP. Biofilm formation by microorganisms in the sinonasal cavity can exacerbate Type 1 inflammation, contributing to persistent infections (5). Biofilms are difficult to treat and often necessitate surgical intervention.

The microbiology of chronic rhinosinusitis differs significantly from that of acute rhinosinusitis and is commonly caused by anaerobes, Gram-negative bacteria, *Staphylococcus aureus*, and fungi (usually *Aspergillus* species and occasionally other moulds). The persistence of infection or extension of unresolved acute rhinosinusitis can lead to a shift in the types of bacteria present from aerobic to anaerobic bacteria. This includes *Pseudomonas aeruginosa*, particularly from patients with cystic fibrosis, *Enterobacterales*, *Peptostreptococcus* species, *Cutibacterium* (Formerly

Propionibacterium) species, *Fusobacterium* species, *Prevotella* species and other anaerobic Gram-negative bacteria (21-24).

Chronic rhinosinusitis can lead to serious and life-threatening complications with the most common being orbital infections (25-27). Intracranial infections are less common but may cause significant morbidity and mortality. Another rare complication is osteomyelitis (see [UK SMI B 42 - Investigation of Bone](#)), involving the frontal bone (Pott's puffy tumour). *Staphylococcus aureus* and anaerobes are the predominant isolates from such cases and are also recovered from children with severe rhinosinusitis symptoms requiring surgical intervention or with protracted rhinosinusitis (lasting over one year) (12).

4.1.3 Fungal rhinosinusitis

Fungal rhinosinusitis can be acute or chronic and is categorised into non-invasive and invasive fungal rhinosinusitis depending on the extent of fungal involvement in the sinuses and the severity of the infection. Non-invasive fungal rhinosinusitis may take the form of a fungus ball in the sinus, saprophytic fungal rhinosinusitis or allergic fungal rhinosinusitis (28-30). Invasive fungal rhinosinusitis can be either acute or chronic and may form granulomas within the sinus cavities. Granulomatous invasive rhinosinusitis may be confused with Granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis) or squamous cell carcinoma (28). Therefore, examination of tissue rather than pus is important in fungal rhinosinusitis and close co-operation among the surgeon, microbiologist and histopathologist is also necessary (8,28). Acute invasive rhinosinusitis can spread rapidly from the involved sinuses and is to be regarded as a medical emergency. Aggressive surgical debridement is often required in addition to systematic antifungal therapy and treatment of the underlying cause.

Fungal rhinosinusitis is predominantly caused by moulds, with *Aspergillus* species being the most common pathogens. Other moulds that are less commonly encountered include *Mucor* and *Rhizopus* which are associated with the fatal invasive fungal infection, mucormycosis (31,32). Also, less common are thermally dimorphic fungi such as *Sporothrix schenckii*, one of the causative agents of endemic mycoses. These exist as tissue invasive yeast at human body temperature and as moulds in the environment (33). They are limited by geographical distribution and rare in the UK.

Community-acquired chronic fungal rhinosinusitis is a relatively common problem in some tropical and subtropical countries which can in some instances lead to invasive disease, e.g., in Africa and India, and imported cases may be encountered (32). The commonest cause overall is *Aspergillus flavus*, but other fungi should be considered.

It is important to take into consideration the country of origin and travel history of patients in suspected cases of fungal rhinosinusitis to help determine the causative agent of infection. Rhino-orbital cerebral mucormycosis, which became more prevalent in India during COVID-19 pandemic, highlights the importance of such considerations in diagnosis and treatment planning (34).

5 Safety considerations

The section covers specific safety considerations (35-55) related to this UK SMI, and should be read in conjunction with the general [safety considerations](#).

5.1 Specimen collection, transport and storage:

Use aseptic technique.

Collect all specimens before antimicrobial or antifungal therapy where possible.

Collect specimens in appropriate CE marked leak-proof containers and transport in sealed plastic bags.

Compliance with postal, transport and storage regulations is essential.

5.2 Specimen handling, processing and examination:

The majority of diagnostic work can be conducted at Containment Level 2. However, specific procedures involving mycology work and certain hazard group 2 bacterial isolates should be conducted within a microbiology safety cabinet.

When Hazard Group 3 organisms are suspected, or clinical details regarding travel history are not available for a risk assessment, all specimens must be processed in a microbiology safety cabinet under full containment level 3 conditions. General containment level 3 procedures are also recommended for the examination of cultures that may contain dimorphic fungi and other pathogenic fungi. Sealed containers such as screw-capped bottles should be used for culture. Culture plates are not suitable.

Any laboratory procedures that give rise to infectious aerosols must be conducted in a microbiological safety cabinet.

Centrifugation must be carried out in sealed buckets which are subsequently opened in a microbiological safety cabinet.

Specimen containers must also be placed in a suitable holder.

Refer to current guidance on the safe handling of all organisms documented in this UK SMI.

The above guidance should be supplemented with local COSHH and risk assessments.

6 Pre-laboratory processes (pre analytical stage)

6.1 Specimen type:

Antral washout, sinus aspirate, sinus washout, and tissue.

Notes:

Nose swabs are not a suitable sample type for the diagnosis of rhinosinusitis although they can be used for screening for nasal carriage of e.g., MRSA or *Candida auris*. However, superficial nasal suction samples and swabs can be used to investigate nasal discharge in patients with nasogastric tube or post ENT surgery.

Endoscopic aspiration is recommended for areas that are challenging to access directly and for reducing the risk of iatrogenic trauma and blood contamination of the samples that may be caused by blind aspiration (56).

The choice of specimen is influenced by the patients' clinical details and the investigation aim. For example, sinus aspiration may be sufficient for the diagnosis of bacterial rhinosinusitis while additional biopsy may be required for the identification of fungal structure and more detailed analysis of tissue changes.

6.2 Specimen collection and handling:

For safety considerations refer to Section 5.

Collect specimens before antimicrobial therapy where possible.

Collect specimens other than swabs into appropriate containers and place in sealed plastic bags.

Ideally, a minimum volume of 1mL for washouts is required to ensure adequate sensitivity.

Numbers and frequency of specimen collection are dependent on clinical condition of patient.

6.3 Specimen transport and storage:

Specimens should be transported and processed as soon as possible.

The volume of specimen influences the transport time that is acceptable. Large volumes of purulent material maintain the viability of anaerobes for longer.

The recovery of fastidious organisms and anaerobes in particular is compromised if the transport time is delayed.

Samples should be kept at room temperature if they are to be processed immediately. Otherwise, refrigeration is preferable to storage at ambient temperature.

7 Laboratory processes (analytical stage)

7.1 Specimen processing:

For safety considerations refer to Section 5.

Standard

Non-mucoid sinus or antral washouts are processed as follows:

- Centrifuge specimen (for antral washouts), unless very mucoid, at 1200 x g for 10 minutes
- Discard most of the supernatant, leaving approximately 0.5mL
- Resuspend the centrifuged deposit in the remaining fluid
- Carry out microscopy and culture

Mucoid specimens are processed by digestion as follows:

- Carry out microscopy
- Add equal volume of a 0.1% solution of N-acetyl cysteine to specimen
- Agitate gently for approximately 10 seconds
- Incubation at 35-37°C for 15 minutes followed by gentle agitation for approximately 15 seconds will assist homogenisation

Note: do not exceed 20 minutes of incubation to avoid overprocessing the sample.

- Inoculate plates

7.2 Microscopy

Refer to [UK SMI TP 39 – Staining procedures](#)

For information on technical limitations refer to [scientific information](#).

Direct microscopic examination of fresh or stained specimens can provide pre-diagnostic information on the presence of fungal structures as culture results may not be available for a few days. This is particularly important for the prompt administration of anti-fungal therapy in immunocompromised patients. However, this method is insensitive and negative results do not rule out a fungal infection as may be the case in the early stages of the infection.

Standard

For mucoid specimens:

Using a sterile loop select the most purulent or blood-stained portion of the specimen and make a thin smear on a clean microscope slide for Gram staining.

For non-mucoid specimens:

Using a sterile pipette place one drop of centrifuged deposit (see section 6.1.2) or neat specimen on to a clean microscope slide. Spread this with a sterile loop to make a thin smear for Gram staining.

Note: If fungal infection is suspected or seen in the Gram stain carry out the supplementary examination.

Supplementary

Using a sterile pipette, place one drop of centrifuged deposit (see section 6.1.2) or neat specimen on a clean microscope slide.

Examine at 10x and 40x magnification using potassium hydroxide (KOH) or enhanced with calcofluor white or blankophor white staining for fungal hyphae.

7.3 Culture

Using a sterile loop inoculate each agar plate with centrifuged deposit (see [UK SMI Q 5 - Inoculation of Culture Media for Bacteriology](#)).

For fungal culture on Sabouraud slopes use a pastette to place 2 - 3 drops of deposit onto the agar.

Table 1: Culture media, conditions, and organisms

Clinical details/ conditions	Specimen	Standard media	Incubation			Cultures read	Target organism(s)
			Temperature °C	Atmosphere	Time		
Rhinosinusitis	Antral washout/ Sinus aspirate/ Sinus washout	Blood agar and / or Staph / Strep selective agar	35 to 37	5 to 10 % CO ₂	40 to 48hrs	daily	Common pathogens: <i>M. catarrhalis</i> <i>S. pneumoniae</i> <i>S. aureus</i> Lancefield Groups A, C, G and F Streptococcus anginosus group Other organisms in pure growth may be significant.
			35 to 37	Air	40 to 48hrs	daily	

Investigation of samples from paranasal sinuses

Clinical details/ conditions	Specimen	Supplementary media	Incubation			Cultures read	Target organism(s)
			Temperature °C	Atmosphere	Time		
Rhinosinusitis	Antral washout/ Sinus aspirate/ Sinus washout	Chocolate agar with or without bacitracin ^a	35 to 37	5 to 10% CO ₂	40 to 48hrs	daily	Common Pathogens: β-haemolytic streptococci Enterobacterales ^b <i>H. influenzae</i> <i>M. catarrhalis</i> Pseudomonads <i>S. aureus</i> <i>S. anginosus</i> group <i>S. pneumoniae</i>
		Neomycin fastidious anaerobe agar with 5 µg metronidazole disc	35 to 37	Anaerobic	48hrs or 5 to 7 days ^c	48hrs and at 5 to 7 days ^c	Common Pathogens: <i>Fusobacterium</i> species <i>Peptostreptococcus</i> species <i>Cutibacterium</i> species <i>Prevotella</i> species

Investigation of samples from paranasal sinuses

Clinical details/ conditions	Specimen	Supplementary media	Incubation			Cultures read	Target organism(s)
			Temperature °C	Atmosphere	Time		
Chronic rhinosinusitis or Rhinosinusitis in immunocompromised patients ^d	Antral washout/ Sinus aspirate/ Sinus washout/ Tissue ^e	Sabouraud dextrose agar supplemented with chloramphenicol or gentamicin ^f	30 to 37 ^g	Air	5 to 7 days ^h	Greater than 40 hrs and at 5 to 7 days ^h	Moulds ⁱ

a May include either a bacitracin 10-unit disc or bacitracin incorporated in the agar. When bacitracin is incorporated into the plate, a separate blood agar plate incubated in 5 to 10% CO₂ will need to be put up to detect *M. catarrhalis* and *S. pneumoniae*.

b Gram-negative selective plate (CLED or MacConkey) could be added for the isolation and differentiation of Gram-negative organisms, including those in the Enterobacterales order.

c Review the plates at 48 hours. If there is no growth and there is a clinical suspicion of slow-growing facultative anaerobes, such as *Cutibacterium acnes* or *Actinomyces* species then re-incubate for 5 to 7 days.

d Immunocompromised patients groups include haematology, oncology, diabetes (uncontrolled), neutropenic (other).

e When testing tissue biopsies, specimens should not be overly processed (e.g., crushed) as this may damage hyphal elements and minimise the chances for isolating the fungus.

f Supplemented with chloramphenicol or gentamicin; chromogenic media may be useful for identifying mixed fungal infections.

g In case of suspected mucormycosis or observation of hyphae of Mucorales in direct microscopy, it is recommended to incubate the cultures at two separate temperatures, 30 °C and 37 °C to increase the yield.

h Moulds are the main fungal pathogens for rhinosinusitis whilst yeast growth normally represents colonisation. Therefore, extended incubation is advocated for a minimum of 5 to 7 days, for all surgical samples and for the investigation of fungal rhinosinusitis in high-risk patients. Plates should be read after 40 hours and at 5 to 7 days. Some fungal pathogens may require extended incubation up to 14 days.

If based on travel history endemic mycoses such as histoplasmosis is suspected, samples should be processed in containment level 3 and all yeasts identified to species level.

i Differentiation between yeast and filamentous forms may require microscopic examination. Wet mounts or stain with lactophenol cotton blue (LPCB) should be used.

For fungal culture, one SAB with chloramphenicol or gentamicin plate should be used per sample and streaked as per routine and standard bacteriology practice. However, increasing the number of plates will increase the sensitivity. It is highly recommended that SAB with chloramphenicol or gentamicin plates be sealed with gas-permeable tape or alternatively placed inside a sealable plastic bag during incubation to avoid cross contamination. Incubation of SAB with chloramphenicol or gentamicin plates in 'automated incubation and imaging' modules may lead to fungal contamination of modules and other cultures. No fungal isolate should be dismissed as a 'contaminant' without full identification.

If microscopy is suggestive of organisms not listed in the target list additional and/or other media may be required.

Laboratory should follow local protocols or manufacturer's instructions for optimal incubation conditions.

7.4 Identification

Refer to individual UK SMIs for organism identification.

Table 2. Minimum level of identification in the laboratory

Target organism	Identification level
Peptostreptococcus species	“anaerobes” level
Cutibacterium species	“anaerobes” level
Fusobacterium species	“anaerobes” level
Prevotella species	“anaerobes” level
β-haemolytic streptococci	Lancefield group level
Enterobacteriaceae	species level
Fungi*	species level (if clinically significant)
H. influenzae	species level
M. catarrhalis	species level
Pseudomonas species	species level
S. aureus	species level
S. anginosus	<i>S. anginosus</i> group level
S. pneumoniae	species level

* Moulds are more commonly associated with rhinosinusitis.

Note: Any organism considered to be a contaminant may not require identification to species level. Organisms may be identified further if clinically or epidemiologically indicated.

7.5 Molecular assays

Molecular methods such as Nucleic Acid Amplification Test (NAAT) and fluorescence *in situ* hybridization have been developed for the rapid detection of fungal species directly from patient specimen. These assays allow for the timely diagnosis of invasive fungal rhinosinusitis from tissue samples and subsequently the prompt initiation of antifungal therapy (57). This is crucial due to the high risk of complications and mortality associated with these types of infections in immunocompromised and diabetic patients. In addition, molecular methods can help overcome some of the challenges encountered with culture-based methods such as false negative results and the identification of rare fungal species (57,58).

There are numerous commercially available assays that have been developed for the detection of fungal organisms ranging from pan fungal to pathogen specific (e.g., *Aspergillus*, Mucorales) assays, with pathogen specific assays having higher sensitivity and faster turnaround time (59,60). The quality of these assays is largely dependent on the analytical range of detection provided by the specific assay, type and volume of specimen, the DNA fungal extraction method and automation of the process to increase sensitivity (60,61). Currently, the validation of NAAT for the diagnosis of fungal rhinosinusitis is relatively limited and it is essential that these assays are validated for the specimen type before their use in laboratories.

Despite the advancement in molecular methods, they are not routinely used for the detection of fungal rhinosinusitis and have not yet replaced culture-based methods in clinical laboratories. These methods would often be used in conjunction with culture-based methods as appropriate or utilised largely by reference laboratories (57,60). Where fungal elements are visualized in specimens but are culture negative, molecular testing may be a useful adjunct test to provide identification (61).

7.6 Antigen/antibody testing

Antigen/antibody tests have many limitations and are not regularly used as diagnostic tools for rhinosinusitis, including invasive fungal rhinosinusitis. Factors that can influence the performance of these assays include variation in sensitivity and specificity depending on the clinical setting e.g., underlying conditions and immunosuppression as well as false positive results due to cross-reactivity e.g., individuals with yeast colonisation (62-64).

Furthermore, antibody tests have limited applicability in the diagnosis of invasive fungal rhinosinusitis, because of the reduced or delayed antibody production in immunocompromised individuals.

8 Post-laboratory processes (post analytical stage)

8.1 Microscopy

8.1.1 Reporting microscopy

Report microscopy results as:

Gram's stain

- Report presence of WBCs.
- Report if organisms detected.

Note: The presence of yeast cells e.g., *Candida* is very rare and usually a reflection of oropharyngeal colonisation. In such cases further histopathological evidence is required.

Fungal stain

- Report presence or absence of fungal elements.
- Differentiate between yeasts and filamentous fungi (moulds).
- Where possible provide a description of the filamentous fungi/element observed.

Notes:

- The presence of fungal structures in biopsy specimens from deep tissues should be reported as clear/proven evidence of fungal infection.
- The presence of broad, aseptate or pauci-septate hyphae with wide-angle branching is consistent with Mucorales. The presence of regularly septate hyphae with 45° branching is consistent with *Aspergillus* species. but could represent other hyaline fungi such as *Scedosporium* species.
- Reports simply stating fungal elements seen with no differentiation, are of limited clinical utility and should be avoided.

8.1.2 Microscopy reporting time

Interim or preliminary results should be issued on detection of clinically significant results as soon as growth is detected unless specific alternative arrangements have been made with the requestors.

In immunocompromised patients or when fungal investigation is specifically requested, microscopy positive fungal results indicating presence of filamentous hyphae indicative of mucoraceous mould (members of Mucorales) or *Aspergillus species* should be immediately communicated to the consultant looking after the patient or an infection consultant liaising with the clinical teams.

Urgent results should be telephoned or transmitted electronically in accordance with local policies.

Final written or computer-generated reports should follow preliminary and verbal reports as soon as possible.

8.2 Culture

8.2.1 Reporting Culture

Report culture results as:

Bacterial Culture

- Clinically significant organisms with antimicrobial susceptibility results
- No growth of clinically significant organisms*
- No growth

* Identification should not be reported for organisms of no clinical significance.

Fungal culture

- Yeasts should be reported along with an indication of growth quantity of scanty/light, moderate or heavy to allow for interpretation of significance.
- Isolation of any filamentous fungi should be reported, irrespective of burden.
- No fungal growth.

Notes

- Fungal growth may be reported as negative after 48 hours incubation although cultures will continue to be incubated up to 5 - 7 days and extended culture (up to 14 days may be required where fungal rhinosinusitis is specifically suspected). In the event of fungal growth, a further report will be issued.
- The presence of fungi should be documented even when a fungal culture is overgrown by chloramphenicol-resistant Gram-negative bacterial (e.g., *Pseudomonas* spp.). This should be noted in the result and not reported as 'fungi not isolated'.
- All clinically significant fungal isolates should be identified to species level (for yeast species, level identification is essential in recurrent or recalcitrant infections).

8.2.2 Culture reporting time

Interim or preliminary results should be issued on detection of clinically significant isolates as soon as growth is detected unless specific alternative arrangements have been made with the requestors.

Urgent results should be telephoned or transmitted electronically in accordance with local policies.

Final written or computer-generated reports should follow preliminary and verbal reports as soon as possible.

See appropriate UK SMIs for supplementary investigations.

8.3 Reporting other tests including molecular testing

As newer and more novel methods are becoming available, their validation and reporting should follow local protocols or manufacturer's instructions.

9 Antimicrobial susceptibility testing

For interpretation of susceptibility testing results, laboratories should test and interpret according to the EUCAST breakpoint, refer to [EUCAST guidelines for breakpoint information](#).

Alternatively, the Clinical and Laboratory Standards Institute (CLSI) method along with the corresponding CLSI breakpoints can be used: [Susceptibility Testing Subcommittees \(clsi.org\)](#).

Alternatively, isolates can be sent to an appropriate specialist or reference laboratory.

Antifungal susceptibility testing should be performed for fungal rhinosinusitis, when a culture is available.

9.1 Reporting of antimicrobial susceptibility testing

Report susceptibilities as clinically indicated. Prudent use of antimicrobials according to local and national protocols is recommended.

10 Referral to reference or specialist testing laboratories

In case of sending away isolates to reference or specialist testing laboratories for processing, ensure that the specimen is placed in the appropriate package and transported accordingly. Follow local regulations and instructions provided by the reference or specialist testing laboratories for sending isolates.

Contact the appropriate reference laboratory (refer to the links provided below) for information on the tests available, turnaround times, transport procedure and any other requirements for sample submission.


[England](#)

[Wales](#)

[Scotland](#)

[Northern Ireland](#)

Algorithm: Investigation of samples from paranasal sinuses



Please see Table 1 for algorithm details. If microscopy is suggestive of organisms not listed in target list, additional and/or other media may be required. In addition, if fungal elements are seen but the culture is negative, molecular identification may be useful.

References

An explanation of the reference assessment used is available in the [scientific information section on the UK SMI website](#).

1. Borman AM, Johnson EM. Name Changes for Fungi of Medical Importance, 2018 to 2019. *J Clin Microbiol* 2021: volume 59, issue 2. **2++**
10.1128/jcm.01811-20
2. Pence MA. Nasal Sinus Cultures. *Clinical Microbiology Procedures Handbook*. 5th ed.; 2023. **++**
3. Chen SCA and others. *Aspergillus, Talaromyces, and Penicillium*. *Manual of Clinical Microbiology*; 2023. pages. 1-32. **++**
4. National Institute for Health and Care Excellence (NICE) Sinusitis: What causes it? Sinusitis; 2024. **++**
5. Orlandi RR and others. International consensus statement on allergy and rhinology: rhinosinusitis 2021. *International Forum of Allergy & Rhinology* 2021: volume 11, issue 3, pages 213-739. **1++** <https://doi.org/10.1002/alr.22741>
6. Fokkens WJ and others. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. *Rhinology* 2020: volume 58, issue Suppl S29, pages 1-464. **++**
10.4193/Rhin20.600
7. Patel ZM, Hwang PH. Acute Bacterial Rhinosinusitis. *Infections of the Ears, Nose, Throat, and Sinuses* 2018: volume 4, pages 133-43. **+**
8. Abdolrasouli A, Howell S. Microscopic Examination of Clinical Specimens. *Clinical Microbiology Procedures Handbook*. 5th ed.; 2023. **++**
9. Deutsch PG and others. Invasive and Non-Invasive Fungal Rhinosinusitis-A Review and Update of the Evidence. *Medicina (Kaunas)* 2019: volume 55, issue 7. **++** 10.3390/medicina55070319
10. National Institute for Health and Care Excellence (NICE). Sinusitis (acute): antimicrobial prescribing; 2017. **+**
11. Sawada S, Matsubara S. Microbiology of Acute Maxillary Sinusitis in Children. *The Laryngoscope* 2021: volume 131, issue 10, pages E2705-E11. **2+**
<https://doi.org/10.1002/lary.29564>
12. Drago L and others. Microbiological Aspects of Acute and Chronic Pediatric Rhinosinusitis. *J Clin Med* 2019: volume 8, issue 2. **++** 10.3390/jcm8020149
13. Brook I. Acute and chronic bacterial sinusitis. *InfectDisClinNorth Am* 2007: volume 21, issue 2, pages 427-48, vii. **+**

14. Cheong I and others. Usefulness of ultrasound in the diagnosis of nosocomial maxillary sinusitis in patients with severe Covid-19 pneumonia: a retrospective study. *J Ultrasound* 2022: volume 25, issue 4, pages 923-7. **2+**
10.1007/s40477-022-00656-5
15. Brook I. Microbiology of chronic rhinosinusitis. *European Journal of Clinical Microbiology & Infectious Diseases* 2016: volume 35, issue 7, pages 1059-68. **+**
10.1007/s10096-016-2640-x
16. Balsalobre Filho LL and others. [Nosocomial sinusitis in an intensive care unit: a microbiological study]. *Braz J Otorhinolaryngol* 2011: volume 77, issue 1, pages 102-6. **2+** 10.1590/s1808-86942011000100017
17. Brook I. Microbiology of nosocomial sinusitis in mechanically ventilated children. *ArchOtolaryngolHead Neck Surg* 1998: volume 124, issue 1, pages 35-8. **2+**
18. Leung AK and others. Acute bacterial sinusitis in children: an updated review. *Drugs Context* 2020: volume 9. **1+** 10.7573/dic.2020-9-3
19. Haloob N, Hopkins C. Moving the Classification of Chronic Rhinosinusitis Away from Polyp/No Polyps. *Current Otorhinolaryngology Reports* 2023: volume 11, issue 4, pages 414-21. **++** 10.1007/s40136-023-00488-9
20. Xu X and others. Highlights in the advances of chronic rhinosinusitis. *Allergy* 2021: volume 76, issue 11, pages 3349-58. **++**
<https://doi.org/10.1111/all.14892>
21. Wagner Mackenzie B and others. Bacterial community collapse: a meta-analysis of the sinonasal microbiota in chronic rhinosinusitis. *Environmental Microbiology* 2017: volume 19, issue 1, pages 381-92. **1+**
<https://doi.org/10.1111/1462-2920.13632>
22. Krawczyk B and others. Escherichia coli Strains with Virulent Factors Typical for Uropathogens were Isolated from Sinuses from Patients with Chronic Rhinosinusitis-Case Report. *Pathogens* 2020: volume 9, issue 5. **3++**
10.3390/pathogens9050318
23. Michalik M, Krawczyk B. Chronic Rhinosinusitis-Microbiological Etiology, Potential Genetic Markers, and Diagnosis. *Int J Mol Sci* 2024: volume 25, issue 6. **++** 10.3390/ijms25063201
24. Lucas SK and others. Diversity of cystic fibrosis chronic rhinosinusitis microbiota correlates with different pathogen dominance. *J Cyst Fibros* 2021: volume 20, issue 4, pages 678-81. **2+** 10.1016/j.jcf.2021.03.022
25. Hong P and others. Evaluating Complications of Chronic Sinusitis. *Case Rep Emerg Med* 2017: volume 2017, pages 8743828. **3+** 10.1155/2017/8743828

26. El Mograbi A and others. Orbital Complications of Rhinosinusitis in the Adult Population: Analysis of Cases Presenting to a Tertiary Medical Center Over a 13-Year Period. *Annals of Otolaryngology, Rhinology & Laryngology* 2019: volume 128, issue 6, pages 563-8. **2+** 10.1177/0003489419832624
27. Serkan Ç A, Serkan K. An Approach to Orbital Complications in Rhinosinusitis. *ENT Updates* 2019: volume 9, issue 3, pages 180-4. **3++** 10.32448/entupdates.576655
28. Montone KT. Pathology of Fungal Rhinosinusitis: A Review. *Head Neck Pathol* 2016: volume 10, issue 1, pages 40-6. **+** 10.1007/s12105-016-0690-0
29. Lumyongsatien J and others. Allergic fungal rhinosinusitis presented as a unilateral nasal mass: A first case report from Thailand and literature review. *Annals of Medicine and Surgery* 2022: volume 84, pages 104855. **3++** <https://doi.org/10.1016/j.amsu.2022.104855>
30. Seo MY and others. Clinical pattern of fungal balls in the paranasal sinuses: our experience with 70 patients. *European Archives of Oto-Rhino-Laryngology* 2019: volume 276, issue 4, pages 1035-8. **2++** 10.1007/s00405-018-5258-z
31. Khanna M and others. Risk of Mucormycosis in Diabetes Mellitus: A Systematic Review. *Cureus* 2021: volume 13, issue 10, pages e18827. **1++** 10.7759/cureus.18827
32. Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis. *J Fungi (Basel)* 2019: volume 5, issue 1. **++** 10.3390/jof5010026
33. Gonzalez-Lara MF, Ostrosky-Zeichner L. Fungal Infections of the Brain. In: Hasbun MDMPHR, Bloch MDMPHKC, Bhimraj MDA, editors. *Neurological Complications of Infectious Diseases*. Cham: Springer International Publishing; 2021. pages. 201-24. **++**
34. Hoenigl M and others. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. *Lancet Microbe* 2022: volume 3, issue 7, pages e543-e52. **1++** 10.1016/s2666-5247(21)00237-8
35. Advisory Committee on Dangerous Pathogens. The Approved List of Biological Agents. Health and Safety Executive 2023. pages 1-39. **++**
36. British Standards Institution (BSI). BS EN12469 - Biotechnology - performance criteria for microbiological safety cabinets 2000. **++**
37. British Standards Institution (BSI). BS 5726:2005 - Microbiological safety cabinets. Information to be supplied by the purchaser and to the vendor and to the installer, and siting and use of cabinets. Recommendations and guidance. 2005. pages 1-14. **++**

38. Centers for Disease Control and Prevention. Guidelines for Safe Work Practices in Human and Animal Medical Diagnostic Laboratories. MMWR Surveill Summ 2012: volume 61, pages 1-102.+
39. Department for Transport and others. Transport of infectious substances UN2814, UN2900 and UN3373 Guidance note number 17/2012 (revision 7). 2013. ++
40. Department of Health. Health Protection Legislation (England) Guidance. pages 1-112. 2010. ++
41. Gizzie N, Adukwu E. Evaluation of Liquid-Based Swab Transport Systems against the New Approved CLSI M40-A2 Standard. J Clin Microbiol 2016: volume 54, issue 4, pages 1152-6.2+ 10.1128/JCM.03337-15
42. Health and Safety Executive. Safe use of pneumatic air tube transport systems for pathology specimens. 2009. ++
43. Health and Safety Executive. Control of Substances Hazardous to Health Regulations. The Control of Substances Hazardous to Health Regulations 2002 (as amended). Approved Code of Practice and guidance L5 (sixth edition). HSE Books. 2013. ++
44. Health and Safety Executive. Risk assessment: A brief guide to controlling risks in the workplace. HSE. 2014. ++
45. Health and Safety Executive, Advisory Committee on Dangerous Pathogens. Management and operation of microbiological containment laboratories. HSE. 2019. ++
46. Health Services Advisory Committee. Safe working and the prevention of infection in clinical laboratories and similar facilities. Books. H 2003. ++
47. Home Office. Public Health Act (Northern Ireland) 1967 Chapter 36. 1967. ++
48. Home Office. Anti-terrorism, Crime and Security Act. 2001. ++
49. Official Journal of the European Communities. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on *in vitro* diagnostic medical devices 1998. pages 1-37. ++
50. Scottish Government. Public Health (Scotland) Act. 2008. ++
51. The Royal College of Pathologists. The retention and storage of pathological records and specimens (5th edition). pages 1-59. 2015. ++
52. The Welsh Assembly Government. Health Protection Legislation (Wales) Guidance. 2010. ++

53. Tyrrell KL and others. Comparison of the Copan eSwab System with an Agar Swab Transport System for Maintenance of Fastidious Anaerobic Bacterium Viability. *J Clin Microbiol* 2016: volume 54, issue 5, pages 1364-7. **2+**
10.1128/JCM.03246-15
54. World Health Organization. Guidance on regulations for the transport of infectious substances 2021-2022. WHO. 2021. **++**
55. UK Health Security Agency (UKHSA). Laboratory reporting to UKHSA: a guide for diagnostic laboratories. UKHSA 2023. pages 1-31. **++**
56. Massey CJ and others. Sample collection for laboratory-based study of the nasal airway and sinuses: a research compendium. *Int Forum Allergy Rhinol* 2020: volume 10, issue 3, pages 303-13. **+** 10.1002/alr.22510
57. Chaturantabut S and others. Identification of pathogens causing invasive fungal rhinosinusitis in surgical biopsies using polymerase chain reaction. *The Journal of Laryngology & Otology* 2020: volume 134, issue 7, pages 632-5. **2++**
10.1017/S0022215120001395
58. Raiesi O and others. Molecular identification and clinical features of fungal rhinosinusitis: A 3-year experience with 108 patients. *Microbial Pathogenesis* 2021: volume 158, pages 105018. **2+**
<https://doi.org/10.1016/j.micpath.2021.105018>
59. Valero C and others. New Panfungal Real-Time PCR Assay for Diagnosis of Invasive Fungal Infections. *Journal of Clinical Microbiology* 2016: volume 54, issue 12, pages 2910-8. **2+** 10.1128/jcm.01580-16
60. Camp I and others. Clinical evaluation of an in-house panfungal real-time PCR assay for the detection of fungal pathogens. *Infection* 2020: volume 48, issue 3, pages 345-55. **2++** 10.1007/s15010-020-01395-7
61. Ashraf MJ and others. Evaluating a semi-nested PCR to support histopathology reports of fungal rhinosinusitis in formalin-fixed paraffin-embedded tissue samples. *Journal of Clinical Laboratory Analysis* 2022: volume 36, issue 2, pages e24209. **2+** <https://doi.org/10.1002/jcla.24209>
62. Melancon CC and others. The role of galactomannan *Aspergillus* antigen in diagnosing acute invasive fungal sinusitis. *International Forum of Allergy & Rhinology* 2019: volume 9, issue 1, pages 60-6. **2+**
<https://doi.org/10.1002/alr.22225>
63. Wei H and others. The values of (1,3)- β -D-glucan and galactomannan in cases of invasive fungal rhinosinusitis. *American Journal of Otolaryngology* 2021: volume 42, issue 2, pages 102871. **2+**
<https://doi.org/10.1016/j.amjoto.2020.102871>

64. Leeflang MM and others. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev 2015: volume 2015, issue 12, pages Cd007394.1+ 10.1002/14651858.CD007394.pub2